What happened with Pacific Edge (ASX:PEB) in its FY26 financial results?

Pacific Edge reported its audited FY26 results, which reflect a tough financial year heavily impacted by a loss of US Medicare coverage that began in April 2025.

How does the inclusion of Triage Plus affect Pacific Edge’s path to profitability?

Triage Plus commands a relatively high Medicare price of US$1,328 per test. Its inclusion in the draft coverage policy is expected to substantially improve the unit economics of operating Pacific Edge's US sales team.

What are Pacific Edge’s (ASX:PEB) key financial metrics for FY26 compared to FY25?

Pacific Edge’s audited FY26 financial metrics showed significant declines due to the temporary loss of Medicare revenue. Operating revenue fell to $11.5 million (down from $21.8 million in FY25), and total revenue dropped to $13.6 million (down from $24.6 million in FY25).

Image for illustrative purposes only. Not a real photo.

Pacific Edge eyes profitability after US Medicare breakthrough

Q: Why does the new US Medicare draft policy matter for Pacific Edge (ASX:PEB)?

The new draft policy, titled 'Urine-based Biomarkers in Patients with Microhematuria' (DL04378), establishes hematuria evaluation as a Medicare benefit for the first time. It specifically covers Pacific Edge’s Cxbladder Triage and Triage Plus tests for intermediate-risk patients.

Written by Liezl GambePublished May. 24 2026Last Updated May. 24 2026

Cancer diagnostics company Pacific Edge (ASX:PEB) reported its audited financial results for the 2026 financial year, marking a period of strategic transition highlighted by a crucial breakthrough in US Medicare policy.

The company announced the achievement of a new draft Local Coverage Determination, 'Urine-based Biomarkers in Patients with Microhematuria' (DL04378).

The milestone establishes haematuria evaluation as a Medicare benefit for the first time, covering both Cxbladder Triage and Triage Plus for intermediate-risk patients.

The inclusion of Triage Plus—which commands a higher Medicare price of US$1,328—is expected to bolster unit economics and accelerate the company's pathway to profitability.

Pacific Edge has also been cleared to pursue claim-by-claim reimbursement for the products ahead of the LCD becoming final, which is anticipated by the end of the 2026 calendar year.

Frequently asked questions

What happened with Pacific Edge (ASX:PEB) in its FY26 financial results?

Why does the new US Medicare draft policy matter for Pacific Edge (ASX:PEB)?

How does the inclusion of Triage Plus affect Pacific Edge’s path to profitability?

What are Pacific Edge’s (ASX:PEB) key financial metrics for FY26 compared to FY25?